The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
about
Glucocorticoids suppress renal cell carcinoma progression by enhancing Na,K-ATPase beta-1 subunit expressionDetermination of cediranib in mouse plasma and brain tissue using high-performance liquid chromatography-mass spectrometry.Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.The effect of AZD2171- or sTRAIL/Apo2L-loaded polylactic-co-glycolic acid microspheres on a subcutaneous glioblastoma model.Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.
P2860
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The vascular endothelial growt ...... human renal tumor xenografts.
@en
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib
@nl
type
label
The vascular endothelial growt ...... human renal tumor xenografts.
@en
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib
@nl
prefLabel
The vascular endothelial growt ...... human renal tumor xenografts.
@en
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib
@nl
P2093
P2860
P1476
The vascular endothelial growt ...... human renal tumor xenografts.
@en
P2093
Dietmar W Siemann
Juliane M Jürgensmeier
W D Brazelle
P2860
P304
P356
10.1016/J.IJROBP.2008.10.031
P407
P577
2009-03-01T00:00:00Z